February 17, 2017 08:09 AM EST

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

John Carroll

Editor & Founder

When Celgene bought out Receptos and its autoimmune drug ozanimod back in 2015 for $7.2 billion in cash, the big biotech bullishly forecast their drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test

In the hunt for a megablock­buster, Cel­gene plans FDA fil­ing in wake of PhI­II win for ozan­i­mod in MS

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test